SCHEMBL317848

SCHEMBL317848

O=[C]ON1C(=O)C=CC1=O

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MGLL Q99685 5/20 0.35
GSK3A P49840 1/20 0.35
GSK3B P49841 1/20 0.35
FAAH O00519 2/20 0.32
ALDH1A1 P00352 2/20 0.31
BLM P54132 2/20 0.31
GMNN O75496 1/20 0.31
LMNA P02545 1/20 0.31
MAPT P10636 1/20 0.31
THPO P40225 1/20 0.31
PMP22 Q01453 1/20 0.31
NPSR1 Q6W5P4 1/20 0.31
BCHE P06276 1/20 0.30
POLB P06746 1/20 0.30
MAOA P21397 1/20 0.30
ACHE P22303 1/20 0.30
MAOB P27338 1/20 0.30
APEX1 P27695 1/20 0.30
MAPK1 P28482 1/20 0.30
CASP1 P29466 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20556202 0.76 MGLL (0.36) MGLLGSK3AGSK3BFAAHNPSR1
SCHEMBL10666060 0.69 MGLL (0.42) MGLLGSK3AGSK3BFAAHALDH1A1
SCHEMBL7139394 0.69 MGLL (0.42) MGLLGSK3AGSK3BFAAHALDH1A1
SCHEMBL319047 0.65 GAA (0.48) ALDH1A1LMNAMAPTNPSR1POLB
SCHEMBL2493031 0.65
SCHEMBL819470 0.65
SCHEMBL712983 0.63 MGLL (0.36) MGLLGSK3AGSK3BFAAHALDH1A1
SCHEMBL21840474 0.61 MGLL (0.35) MGLLGSK3AGSK3BFAAHALDH1A1
SCHEMBL9728517 0.61 MGLL (0.41) MGLLGSK3AGSK3BFAAHALDH1A1
SCHEMBL5071662 0.61 ALDH1A1 (0.35) MGLLGSK3AGSK3BFAAHALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024059119-A2 COMPOUNDS AND THEIR USE IN FILTERING ULTRAVIOLET AND/OR HIGH-ENERGY VISIBLE LIGHT SOLIOME, INC. (US) 2024-03-21 WO claimed
WO-2021034729-A1 N-ARYL SULFONAMIDE DERIVATIVES AS VACCINE ADJUVANT THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2021-02-25 WO claimed
WO-2024059119-A2 COMPOUNDS AND THEIR USE IN FILTERING ULTRAVIOLET AND/OR HIGH-ENERGY VISIBLE LIGHT SOLIOME, INC. (US) 2024-03-21 WO disclosed
WO-2021034729-A1 N-ARYL SULFONAMIDE DERIVATIVES AS VACCINE ADJUVANT THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2021-02-25 WO disclosed
US-8093405-B2 Formation of 18F and 19F fluoroarenes bearing reactive functionalities UNIVERSITY OF NEWCASTLE UPON TYNE (GB) 2012-01-10 US disclosed
EP-2310362-A1 FORMATION OF 18F AND 19F FLUOROARENES BEARING REACTIVE FUNCTIONALITIES University Of Newcastle-Upon Tyne (GB) 2011-04-20 EP disclosed
WO-2009138763-A1 FORMATION OF 18F AND 19F FLUOROARENES BEARING REACTIVE FUNCTIONALITIES UNIVERSITY OF NEWCASTLE UPON TYNE (GB) 2009-11-19 WO disclosed
US-20090286992-A1 FORMATION OF 18F AND 19F FLUOROARENES BEARING REACTIVE FUNCTIONALITIES UNIVERSITY OF NEWCASTLE UPON TYNE (GB) 2009-11-19 US disclosed
US-5374516-A Covalently attached to polymer particles of ethylenically unsaturated monomers with reactive alkylsulfonyl or halogen groups; detecting hormones, drugs, steroids in urine, blood, saliva EASTMAN KODAK COMPANY (US) 1994-12-20 US disclosed
EP-0302715-B1 AVIDIN- AND BIOTIN-IMMOBILIZED REAGENTS, ANALYTICAL ELEMENTS AND METHODS OF USE EASTMAN KODAK COMPANY (a New Jersey corporation) (US) 1992-04-22 EP disclosed
EP-0370694-A2 Diagnostic kit and method using a solid phase capture means for detecting nucleic acids EASTMAN KODAK COMPANY (US) 1990-05-30 EP disclosed
EP-0302715-A1 Avidin- and biotin-immobilized reagents, analytical elements and methods of use EASTMAN KODAK COMPANY (a New Jersey corporation) (US) 1989-02-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090286992-A1 FORMATION OF 18F AND 19F FLUOROARENES BEARING REACTIVE FUNCTIONALITIES RARB, RARG, RARA MGLL 4447/4885GSK3A 4801/4885GSK3B 4783/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.